Position in SCYX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$304,621
+$93,124 QoQ
Shares Held
332,194
-0.7% QoQ
Ownership
0.418%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#12
of 44 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in SCYX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026BlackRock, Inc. holds $19,745,764,999 across 67 Drug Manufacturers - Specialty & Generic names. SCYX ranks #50 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
35,584,312 | $4,206,421,510 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
5,399,649 | $3,201,883,855 | |
| 3 | TEVA |
Teva Pharmaceutical Industries Ltd
|
65,136,464 | $1,961,910,288 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
13,385,607 | $1,763,419,854 | |
| 5 | VTRS |
Viatris Inc
|
84,359,804 | $1,139,700,941 | |
| 6 | ELAN |
Elanco Animal Health Inc
|
47,622,630 | $1,139,609,527 | |
| 7 | ALKS |
Alkermes plc.
|
28,314,410 | $1,001,197,527 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
8,183,193 | $620,695,182 |
All Filings in SCYX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $304,621 | 332,194 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $211,497 | 334,648 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $257,678 | 334,648 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $225,887 | 334,648 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $402,048 | 422,322 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $515,718 | 426,214 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $634,207 | 425,643 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||